FDA Blessing Sought for 'Modified Risk' Tobacco Product

    Niche tobacco company Star Scientific is seeking the U.S. Food and Drug Administration's (FDA) approval to sell its wintergreen-flavored, dissolvable tobacco lozenges as 'modified risk' products, the Associated Press reported Feb. 22.

    The company contends that the Ariva-BDL lozenges don't have detectable levels of cancer-causing agents found in other tobacco products, although they do contain addictive nicotine.

    The FDA is currently working on guidelines for classifying 'modified-risk' tobacco products. Star Scientific wants to market Ariva-BDL to smokers as “a useful alternative — with greatly reduced toxin levels,” according to the company.

    By Partnership Staff
    February 2010

    Published

    February 2010

    We use cookies to improve your experience and serve you relevant information. To learn more, read our privacy policy.
    I accept